Intellectual capital and competitive advantages:the case of TTY Biopharm Company by Chen, M. (Ming-Chin)
      Journal of Business Chemistry Vol. 1, Issue 1 May 2004 
 
 
© 2004 Institute of Business Administration                               14  ISSN 1613-9615  
 
 www.businesschemistry.org 
 
 
 
Research Paper 
 
 
 
Intellectual capital and competitive advantages: the case of TTY 
Biopharm Company 
 
 
Ming-Chin Chen*# 
 
* Professor of Accounting, Department of Accounting, National Chengchi University (Taiwan) 
# Correspondence to: mingchin@nccu.edu.tw 
 
 
 
 
Abstract: By conducting indepth interviews with the CEO and top management of TTY Biopharm 
Company, a Taiwan-based pharmaceutical company, I depict the role of TTY’s intellectual capital in building 
competitive advantages and enhancing the achievement of corporate strategies. TTY’s success illustrates that 
even in a relatively small pharmaceutical market such as Taiwan, where a full-range new drug R&D, covering 
from discovering new chemicals to developing new drugs, seems economically infeasible, adopting fit R&D 
strategies and developing intellectual capital to establish competitive advantages can overcome the limitations 
in home market size and bear fruitful results. 
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Introduction 
Intellectual capital includes human capital and 
structural capital wrapped up in customers, 
processes, databases, brands, and systems 
(Edvinsson and Malone 1997),1 and has been 
playing an increasingly important role in creating 
corporate wealth and growth (Lev and Zarowin 
1999).2 The growing divergence between firms’ 
market value and book value shows that much of 
the source of economic value is no longer the 
production of material goods, but the creation of 
intellectual capital (Goldfinger 1997). Cañibano et 
al. (2000) summarized an extensive body of 
empirical evidence on the value relevance of 
investments in intellectual capital such as R&D, 
advertising, patents, brands and trademarks, 
customer satisfaction, human resources. 
Pharmaceutical industry is heavily 
characterized as one of the most innovative, 
knowledge-based, and R&D-intensive industries. 
The innovation in the industry has been in a large 
measure driven by the persistent and successful 
pharmaceutical R&D effort (Aboody and Lev 
2001).3 As innovation becomes key to success in 
the pharmaceutical industry, pharmaceutical 
companies usually needs vast investment in a new 
drug R&D and takes lengthy processes to launch a 
new drug to the market. Consequently, it demands 
a sizable product market to support the mega 
R&D costs. 
                                                     
1 There is no universal definition of intellectual capital and 
its classification until today. To conserve space, this 
study will not review the definitions and classifications 
of intellectual capital in prior literature. 
2 Over the period of 1973-1992, the market-to-book ratios 
of US corporations increased from 0.81 to 1.69, 
implying that about 40% of corporate market value did 
not reflect in financial reporting (Lev and Zarowin 
1999). 
3 Based on data from Chemical & Engineering News, 
October 25, 1999, pp. 62-64, Aboody and Lev (2001) 
reported that over the 10-year period 1989-1998, the 
R&D spending of the major pharmaceutical companies 
increased at an average annual rate of 22% per year, 
from $3.35 billion in 1989 to $10.08 billion in 1998, and 
their patent activity has increased from 800 in 1989 to 
1,115 in 1998. 
Given the small home market size,4 
pharmaceutical companies in Taiwan may not 
afford the vast costs of a whole-range new drug 
R&D, covering from discovering new chemicals to 
developing new drugs. Therefore, most 
pharmaceutical companies in Taiwan are 
essentially generic drug manufacturers. The 
competition for this type companies mainly 
focuses on low costs and low prices. 
Established in 1960, TTY Biopharm 
Company (hereafter, TTY) used to be a traditional, 
generic drug pharmaceutical company that focused 
on production and sales. Due to the keen price-
cutting competition and deteriorating in generic 
product margins, TTY was once close to being 
bankrupt. However, in 1996 a new management 
team came in TTY and started reforming and 
repositioning the company. It initiated the strategy 
of branding generic drugs to differentiate from 
other generic manufacturers. To carry out this 
strategy, TTY began to build up new drug 
development capabilities to enhance product 
brand and quality. The approach achieved great 
success in increasing sales margins and promoting 
the company’s image, helping TTY to leave out 
the endless price-cutting competition in the 
generic drug market and, thus, can channel more 
cash into long-term new drug development. The 
transition runs fairly well. In 2001, the company 
successfully launched IPO in Taiwan OTC 
technology listings and its registered capital 
increased triply from (US) $4.29 million5 in 1997 to 
$14.29 million in 2003.6  
Using the case study methods, this paper is to 
investigate TTY’s intellectual capital and depict the 
role of TTY’s intellectual capital in enhancing its 
key successful factors to achieve corporate 
strategies. In their conceptual intellectual capital 
model, Roos et al. (1998, p.63) also emphasized 
                                                     
4 The main pharmaceutical market worldwide lies in the 
United States, Europe, and Japan, accounting for nearly 
eighty percent of the global sales. The pharmaceutical 
sales in Taiwan constitutes less than one percent of the 
global sales. For detailed discussions of the 
pharmaceutical industry in Taiwan, see Development 
Center for Biotechnology. (2002). 
5 In this study, the dollar amount is converted into US 
dollar. The exchange rate of Taiwan dollar to US dollar 
is assumed to be 35:1. 
6 TTY Biopharm Company Limited. (2002). 
      Journal of Business Chemistry Chen May 2004 
 
 
© 2004 Institute of Business Administration                               16  ISSN 1613-9615  
 
 www.businesschemistry.org 
that in cultivating and managing intellectual capital, 
selected measures for intellectual capital should 
link to firms’ key successful factors derived from 
corporate strategies. Therefore, this study is 
expected to have contribution to illustrating Roos 
et al.’s conceptual model by analyzing the case 
company’s transformation and intellectual capital 
management. 
 
TTY’s intellectual capital and 
competitive advantages 
Figure 1 depicts the role of TTY’s intellectual 
capital in supporting the achievement of corporate 
visions, strategies, and competitive advantages. 
Having successfully transformed from a traditional 
generic manufacturer into a new drug 
development company, TTY’s vision now is 
seeking to be an innovative biopharmaceutical 
company specializing in anti-cancer drugs in Asia 
and focusing on new drugs for prevalent Chinese 
diseases. 
In light of the increasing competition in 
pharmaceutical industry, TTY identifies five key 
successful factors (KSFs), including (1) bring 
corporate strategies into operation, (2) recruiting 
and training right people, (3) effective manage-
ment of pipeline and portfolio, (4) becoming a 
preferred partner for strategic alliances, and (5)                        
Competitive Strategies including differentiation, market, internationaland international alliances.
Differentiation: (1) Products differentiation: focusing on Six Four main disease drugs in 
specialization areas, offering total services.
(2) Positioning differentiation: focusing on prevalent Chinese diseases in 
global AsialAsian industrial value chain- marketing-oriented research
development company, focusing on prevalent Chinese diseases.
Market: Efficiently: Using using experienced sophisticated marketing and clinical 
trial abilities capabilities to develop and integrate Taiwan and China markets.
International alliances: Participating in the early-stage R&D of international biotech companies, and 
sharing Asian intellectual property rights.
Intellectual Capital and Key Successful Factors
(See discussions in Section II)
Value-creating Results:
(1) yield the top (see next page) financial performances among Taiwan pharmaceutical companies,
(2) achieve 4 new formulation and 5 new indication R&D results,
(3) accomplish 43 clinical trials, and
(4) receive 3 prominent awards and honors from Taiwan government.
Competitive
Advantage Analysis 
(See Figure 4)
SWOT Analysis
(See Table 1 in Section
Three)
Visions
• To be one of the most innovative biopharmaceutical 
companies specializing in anti-cancer drugs in Asia
• To be the first international biopharmaceutical
company focusing on prevalent Chinese diseases
 
Figure 1: An Illustration of the relationship between TTY’s intellectual capital and corporate 
visions, strategies, and competitive advantages. 
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reducing time to reach the highest sales. TTY’s 
intellectual capital plays an important role in 
enhancing those key successful factors. 
The first KSF is related to the execution of 
corporate strategies. TTY positions itself as a 
marketing-oriented, new drug development 
company.  In order to demand high prices for its 
branded new drugs, TTY focuses its major 
relational capital on large hospitals.7 In developing 
innovative capital, TTY’s R&D strategy is not to 
conduct a whole-range new drug R&D. Instead, it 
focuses on the phase III new drug development, 
which includes developing new indication and new 
formulation drugs. Consistent with the company’s 
self-positioning, the phase III development is the 
closet stage to the product market; therefore, 
focusing on this stage can limit TTY’s R&D risks 
and expedite the payback periods. Table 1 
compares TTY’s R&D intensity, gross margins, 
and growth rates with other pharmaceutical 
companies listed in Taiwan stock market. 
Although TTY invested in the highest R&D 
intensity, it remains to be the most profitable and 
fast growing company.8  
                                                     
7 Large hospitals are more willing to attach greater value to 
product quality; yet, small hospitals are usually more 
cost-conscious. About 65% of TTY’s total revenues now 
come from hospitals. 
8 The rapid growth rate may be, in part, due to the firm size 
of TTY is not large. However, we do believe that TTY’s 
marketing strategy is key to bringing superior sale 
In supporting of the KSF of recruiting and 
maintaining quality work force, TTY stresses on 
investment in human resources. Its average 
employee training and education costs are one of 
the highest among Taiwan’s listed companies. The 
payoff for TTY’s investment in human capital is 
quite fruitful. The company’s average employee 
productivity increased from $108,000 in 2000 to 
$148,200 in 2002.9 
To reduce time to reach the highest sales, 
TTY’s strategy is to invite its major customers to 
participate in the early stage of new drug R&D, 
thereby developing products better fit customers’ 
needs. Co-developing new drug with physicians 
not only expands the company’s innovative capital, 
but enhances relational capital with major 
customers as well. Figure 2 summarizes TTY’s 
optimalization capability of the marketing-oriented 
development strategy in building its core 
competitive edges. Based on its strategic position, 
TTY devotes substantial resources to building 
solid distribution channels with large hospitals and 
medical centers.10  
 
 
                                                                                       
growth rate to its counterparts. 
9 The average employee productivity is calculated by net 
sales divided by number of employees. 
10 TTY’s marketing expenses account for about 30% of its 
sales revenues. 
 
Company Chinese 
Chemical 
Yung 
Shin 
Standard 
Chemical 
Sin-pharma Yung Ri Chi 
Cheng 
TTY 
Total assets 
(in millions) 178 151 74 45 16 39 48 
Net Sales  
(in millions) 69 68 36 24 7 11 36 
R&D %* 5,5 8,7 5,3 8,4 5,7 1,4 11,5 
Cross 
profit% 31,9 65 51 45 38,7 39 67,7 
1998-2002 
growth rate 15,5 -3,5 31,6 44,1 25,1 29,2 121 
 
  Table 1: A Comparison of R&D, gross profits, and growth rates among Taiwan listed    
   pharmaceutical companies in 2002. 
* R&D% is measured by R&D expenditures divided by net sales. 
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Physicians of large hospitals and 
medical centers are more willing to use new 
treatments and new drugs for patients. 
Feedbacks from them often provide the 
direction for future new drug development. 
Finally, TTY’s innovative capital and 
relational capital also bring the advantages in 
seeking international strategic alliances. By 
establishing expertise and clinical experiences 
in prevalent Chinese diseases as well as 
distribution channels in Chinese drug 
market, TTY is well equipped as a preferred 
partner for international pharmaceutical 
giants seeking to enter the Chinese market. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Value-creating Results 
TTY’s successful transformation brings 
fruitful results in both financial and nonfinancial 
performances. TTY’s financial performances 
yielded leaped growth, with sales growing from 
$22.6 million in 2000 to $35.6 million in 2002 and 
EPS growing from $0.05 in 2000 to $0.17 in 2002, 
on a retrospective basis.11 
TTY’s financial performances come from its 
advancements in R&D results. It is the first 
company in Taiwan and the third in the world to 
launch the liposomal (nanotechnology) 
formulations. In addition, the company’s new 
                                                     
11 The par value of common stocks in Taiwan is ten 
(Taiwan) dollars per share, about (US) $0.29. 
Channel
operating
Su
pp
or
t
O
rie
nt
Strategic
position
Medical centers
Large hospitals
New drug 
Development
R&D
Human capitalresources are the 
foundation for creating:
• Innovativeinnovative capital and 
developing relational capital-enhance latest 
knowledge, R&D, regulatory experiences
• Relational-clinical trials co-developed with 
physicians.
Respond to new 
drug demand
Benefits:
Developing a close relation with physicians
Providing better products fit physicians needs
Forming strategic alliance with physicians
Providing physicians with 
latest medical developments, 
treatment technologies, etc.
Market:
- large hospitals
Product:
- differentiation
& focus
Marketing 
capability
 
Figure 2: TTY’s core competitive advantage: Marketing-oriented 
development strategy and optimalization capability. 
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indication development has successfully launched 
several anti-cancer drugs in both Taiwan and 
overseas markets. During 2001-2003, TTY 
received three prominent awards and honors from 
Taiwan government in recognition of its 
technological innovation and achievements in the 
pharmaceutical industry. 
Conclusions and discussions 
Given Taiwan’s small pharmaceutical market 
size, it seems economically infeasible to support 
the whole phases of a new drug R&D, covering 
from discovering new chemicals to developing 
new drugs. However, TTY’s success illustrates that 
even in a relatively small home market size, 
adopting adequate R&D strategies and investing in 
intellectual capital can bear fruitful results. By 
developing intellectual capital, the company is able 
to maintain quality workforce, enhance relations 
with stakeholders, fulfill fit R&D strategies, and 
establish a supportive organization. 
Despite recognizing the importance of 
intellectual capital and considerably investing in it, 
TTY, like many other companies, still has not 
developed appropriate measures for intellectual 
capital. As executives and employees paid 
attention to what they measured and could not 
manage well what they were not measuring 
(Kaplan and Norton 2004, p.6), the lack of 
measures makes TTY difficult to objectively 
evaluate and monitor the changes in intellectual 
capital. Further, Kaplan and Norton (2004, p.13) 
indicate that the value of intangible assets derives 
from their ability to help the organization 
implement its strategy. Therefore, the value of 
intellectual capital depends on how it helps achieve 
corporate strategies.12 In developing intellectual 
capital that can effectively help achieve corporate 
strategies, it is essential to identify and focus on 
those intellectual capital indicators that closely link 
to firms’ key successful factors for achieving 
corporate strategies. Delineating strategy-related 
intellectual capital indicators needs deliberate 
effort and is a difficult task. However, it is crucial 
for companies to effectively link intellectual capital 
                                                     
12 Porter (1996) suggests that an organization’s strategy is 
about selecting the set of activities to create a 
sustainable difference in the marketplace, e.g., cost-
efficient or product differentiation. 
to strategy-implementation and, more importantly, 
to convey the value of intellectual capital to 
outside stakeholders.  
Finally, the success of TTY’s transformation 
also has implications for pharmaceutical 
companies in developing countries. Cost-efficiency 
is, in general, an important competitive edge for 
developing countries. However, the long product 
life cycle and low production costs in the 
pharmaceutical industry suggest that the 
competition in the pharmaceutical market does not 
lie in cost-efficiency, but in innovation and 
product quality. Creating own high-value core 
products is crucial for pharmaceutical companies 
to build sustainable competitive advantages, and, 
thus, risk-taking is inescapable for the executives 
of pharmaceutical companies. However, it might 
be economically infeasible for most 
pharmaceutical companies in developing countries 
to compete with those global pharmaceutical 
giants in new drug R&D. Therefore, to have a role 
in the global market, it is essential for 
pharmaceutical companies in developing countries 
to define their niche position in the industrial value 
chain and then develop strategy-related intellectual 
capital to build up sustainable competitive 
capability. 
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